Biosimilar Clinical Development: Scientific Considerations and New Methodologies | Agenda Bookshop Skip to content
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Kerry B. Barker
B01=PhD Jin
B01=Sandeep M. Menon
B01=Siyan Xu
B01=Sr. D'Agostino
Category1=Non-Fiction
Category=JHB
Category=MBNS
Category=MMG
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Temporarily unavailable
Price_€50 to €100
PS=Active
softlaunch

Biosimilar Clinical Development: Scientific Considerations and New Methodologies

★★★★★
★★★★★

English

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

See more
€51.29
€56.99
Save 10%
Age Group_Uncategorizedautomatic-updateB01=Kerry B. BarkerB01=PhD JinB01=Sandeep M. MenonB01=Siyan XuB01=Sr. D'AgostinoCategory1=Non-FictionCategory=JHBCategory=MBNSCategory=MMGCOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Temporarily unavailablePrice_€50 to €100PS=Activesoftlaunch

Will deliver when available.

Product Details
  • Weight: 500g
  • Dimensions: 156 x 234mm
  • Publication Date: 18 Dec 2020
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9780367736521

About

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer Dr. Ralph DAgostino is a professor of Mathematics and Statistics at Boston University Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept